Synapse - Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)

Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL) Meeting Abstract

Authors:	Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; Yahalom, J.; Rademaker, J.; Dogan, A.; Seshan, V.; Younes, A.
Abstract Title:	Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
Meeting Title:	15th International Conference on Malignant Lymphoma
Journal Title:	Hematological Oncology
Volume:	37
Issue:	Suppl. 2
Meeting Dates:	2019 Jun 18-22
Meeting Location:	Lugano, Switzerland
ISSN:	0278-0232
Publisher:	Wiley Blackwell
Date Published:	2019-06-01
Start Page:	331
End Page:	332
Language:	English
ACCESSION:	137029154
DOI:	10.1002/hon.143_2630
PROVIDER:	EBSCOhost
PROVIDER:	cin20
PUBMED:	31187525
DOI/URL:	http://search.ebscohost.com/login.aspx?direct=true&db=cin20&AN=137029154&site=ehost-live
Notes:	Meeting abstract: 279 -- Accession Number: 137029154 -- Entry Date: In Process -- Revision Date: 20190620 -- Publication Type: Article -- Supplement Title: Jun2019 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20